価格表

在庫・価格 : 2024年05月05日 07時12分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Proteome Profiler Human Phospho-RTK Array Kit
データシート※最新のデータシートでない場合があります
ARY001B RSDアールアンドディー システムス
R&D Systems, Inc.
1 kit ¥133,000 2個 追加

在庫・価格 : 2024年05月05日 07時12分 現在

Proteome Profiler Human Phospho-RTK Array Kit

  • 商品コード:ARY001B
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥133,000
  • 在庫:2個
使用文献
No. 文献情報 備考 参照
1 Lorenzon E et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 2012 Jun;31(26):3136-47
Lorenzon E et al
2012/01/01
Sample Type: Cell Lysates PubMed
2 Gowrishankar K et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol. 2012 Jul;132(7):1850-9
Gowrishankar K et al
2012/01/01
Sample Type: Cell Lysates PubMed
3 Ho AL et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012 Sep;72(17):4515-25
Ho AL et al
2012/01/01
Sample Type: Cell Lysates PubMed
4 Kotani N et al. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J. Biol. Chem. 2012 Oct;287(44):37109-18
Kotani N et al
2012/01/01
Sample Type: Cell Lysates PubMed
5 Joshi AD et al. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE 2012;7(10):e44372
Joshi AD et al
2012/01/01
Sample Type: Cell Lysates PubMed
6 Lin SP et al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS ONE 2012;7(11):e49605
Lin SP et al
2012/01/01
Sample Type: Cell Lysates PubMed
7 Duncan JS et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012 Apr;149(2):307-21
Duncan JS et al
2012/01/01
Sample Type: Tissue Homogenates PubMed
8 Purushothaman A et al. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J. Biol. Chem. 2012 Nov;287(49):41288-96
Purushothaman A et al
2012/01/01
Sample Type: Cell Lysate PubMed
9 Montero JC et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2014 Jan;33(2):148-56
Montero JC et al
2014/01/01
Sample Type: Cell Lysates PubMed
10 Britschgi A et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl. Acad. Sci. U.S.A. 2013 Mar;110(11):E1026-34
Britschgi A et al
2013/01/01
Sample Type: Cell Lysates PubMed
11 Kwon HS et al. Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling. J. Biol. Chem. 2013 Sep;288(37):26357-71
Kwon HS et al
2013/01/01
Sample Type: Cell Lysates PubMed
12 Ugurel S et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin. Cancer Res. 2014 Jan;20(2):499-510
Ugurel S et al
2014/01/01
Sample Type: Tissue Lysate PubMed
13 Lei H et al. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α. Mol. Cell. Biol. 2014 Jan;34(1):110-22
Lei H et al
2014/01/01
Sample Type: Cell Lysates PubMed
14 Son MY et al. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency. Hum. Mol. Genet. 2014 Apr;23(7):1802-16
Son MY et al
2014/01/01
Sample Type: Whole Cells PubMed
15 Drake JM et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl. Acad. Sci. U.S.A. 2013 Dec;110(49):E4762-9
Drake JM et al
2013/01/01
Sample Type: Homogenized Tissue PubMed
16 Skoda J et al. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol. Rep. 2014 Jan;31(1):480-7
Skoda J et al
2014/01/01
Sample Type: Cell Lysates PubMed
17 de-Freitas-Junior JC et al. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. PLoS ONE 2013;8(11):e81579
de-Freitas-Junior JC et al
2013/01/01
Sample Type: Cell Lysates PubMed
18 Lekawanvijit S et al. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS ONE 2013;8(12):e83687
Lekawanvijit S et al
2013/01/01
Sample Type: Cell Lysates PubMed
19 Carlino MS et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014 May;8(3):544-54
Carlino MS et al
2014/01/01
Sample Type: Whole Cells PubMed
20 Sakanyan V et al. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. Sci Rep 2014;4:3977
Sakanyan V et al
2014/01/01
Application: Phosphorylation array, Sample Type: Cell Lysate PubMed
21 Camorani S et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. Mol. Ther. 2014 Apr;22(4):828-41
Camorani S et al
2014/01/01
Sample Type: Cell Extract PubMed
22 Banerjee J et al. Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLoS ONE 2014;9(3):e89239
Banerjee J et al
2014/01/01
Sample Type: Cell Lysates PubMed
23 Miyagawa-Yamaguchi A et al. Expressed glycosylphosphatidylinositol-anchored horseradish peroxidase identifies co-clustering molecules in individual lipid raft domains. PLoS ONE 2014;9(3):e93054
Miyagawa-Yamaguchi A et al
2014/01/01
Sample Type: Whole Cells PubMed
24 Cuenca-L坦pez MD et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014;14:302
Cuenca-L坦pez MD et al
2014/01/01
Sample Type: Whole Cells PubMed
25 Wang LK et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS ONE 2014;9(5):e96765
Wang LK et al
2014/01/01
Sample Type: Whole Cells PubMed
26 Wang J et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 2014 Jun;
Wang J et al
2014/01/01
Sample Type: Cell Lysates PubMed
27 Outani H et al. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer 2014;14:455
Outani H et al
2014/01/01
Sample Type: Cell Lysate PubMed
28 Shiono M et al. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. Sci Rep 2014;4:5927
Shiono M et al
2014/01/01
Sample Type: Cell Lysate PubMed
29 Imura Y et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol. Cancer 2014;13:185
Imura Y et al
2014/01/01
Sample Type: Cell Lysates PubMed
30 Puzanov I et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res. 2015 Feb;21(4):701-11
Puzanov I et al
2015/01/01
Sample Type: Whole Cells PubMed
31 Zemskova MY et al. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell. Signal. 2015 Jan;27(1):135-46
Zemskova MY et al
2015/01/01
Sample Type: Cell Lysate PubMed
32 Tworkoski K et al. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J. Virol. 2015 Mar;89(5):2590-602
Tworkoski K et al
2015/01/01
Sample Type: Whole Cells PubMed
33 Wu JR et al. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS ONE 2015;10(1):e0114495
Wu JR et al
2015/01/01
Sample Type: Cell Lysates PubMed
34 Laukkanen MO et al. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI. PLoS ONE 2015;10(3):e0121441
Laukkanen MO et al
2015/01/01
Sample Type: Cell Lysates PubMed
35 Ito K et al. Artificial human Met agonists based on macrocycle scaffolds. Nat Commun 2015;6:6373
Ito K et al
2015/01/01
Sample Type: Whole Cells PubMed
36 Broecker-Preuss M et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer 2015;15:184
Broecker-Preuss M et al
2015/01/01
Sample Type: Cell Lysates PubMed
37 Lee H et al. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol. Cell. Biol. 2013 Apr;33(7):1430-41
Lee H et al
2013/01/01
Sample Type: Whole Cells PubMed
38 Li L et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene 2014 Aug;33(33):4253-64
Li L et al
2014/01/01
Sample Type: Cell Lysates PubMed
39 Song W et al. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 2014 May;74(9):2444-54
Song W et al
2014/01/01
Sample Type: Cell Lysate PubMed
40 Calero R et al. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS ONE 2014;9(4):e95628
Calero R et al
2014/01/01
Sample Type: Protien Lysates PubMed
41 Ji Z et al. MITF Modulates Therapeutic Resistance through EGFR Signaling. J. Invest. Dermatol. 2015 Jul;135(7):1863-72
Ji Z et al
2015/01/01
Sample Type: Cell Lysates PubMed
42 Chung S et al. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS ONE 2015;10(8):e0134948
Chung S et al
2015/01/01
Sample Type: Cell Lysates PubMed
43 Song A et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Clin. Cancer Res. 2015 May;21(10):2379-87
Song A et al
2015/01/01
Sample Type: Cell Lysates PubMed
44 Cohen NA et al. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res. 2015 May;75(10):2061-70
Cohen NA et al
2015/01/01
Sample Type: Cell Lysates PubMed
45 Heim EN et al. Biologically active LIL proteins built with minimal chemical diversity. Proc. Natl. Acad. Sci. U.S.A. 2015 Aug;112(34):E4717-25
Heim EN et al
2015/01/01
Sample Type: Cell Lysates PubMed
46 Yoshida T et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE 2016;11(1):e0147344
Yoshida T et al
2016/01/01
Sample Type: Cell Lysates PubMed
47 Szymanska E et al. Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway. Cell. Signal. 2016 Jan;28(1):160-71
Szymanska E et al
2016/01/01
Sample Type: Cell Lysates PubMed
48 Huang M et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J. Clin. Invest. 2016 May;126(5):1801-14
Huang M et al
2016/01/01
Sample Type: Cell Lysates PubMed
49 Brandt A et al. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE 2016;11(5):e0155561
Brandt A et al
2016/01/01
Sample Type: Cell Lysates PubMed
50 Aghajanian H et al. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. Nat Commun 2016 Jun;7:12038
Aghajanian H et al
2016/01/01
Sample Type: Whole Cells PubMed
51 Cassinelli G et al. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget 2016 Jul;7(30):47848-47863
Cassinelli G et al
2016/01/01
Sample Type: Cell Lysates PubMed
52 Xu Y et al. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget 2016 Oct;7(43):70080-70091
Xu Y et al
2016/01/01
Sample Type: Cell Lysates PubMed
53 Nanjo S et al. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol. Cancer Ther. 2017 Mar;16(3):506-515
Nanjo S et al
2017/01/01
Sample Type: Cell Lysates PubMed
54 Saintas E et al. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. PLoS ONE 2017;12(2):e01
Saintas E et al
2017/01/01
Sample Type: Cell Lysate PubMed
55 Nukaga S et al. Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2017 Apr;77(8):2078-2089
Nukaga S et al
2017/01/01
Sample Type: Cell Lysates PubMed
56 Buchanan PC et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J. Biol. Chem. 2017 Apr;292(15):6339-6351
Buchanan PC et al
2017/01/01
Sample Type: cell supernates PubMed
57 Li C et al. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2017 Apr;114(14):E2852-E2861
Li C et al
2017/01/01
Sample Type: Cell Lysates PubMed
58 Yadav SS et al. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol 2017 Jun;10(3):357-366
Yadav SS et al
2017/01/01
Sample Type: Cell Lysates PubMed
59 Xu L et al. BCL6 promotes glioma and serves as a therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 2017 04;114(15):3981-3986
Xu L et al
2017/01/01
Sample Type: Cell Lysates PubMed
60 Adelaiye-Ogala R et al. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res. 2017 12;77(23):6651-6666
Adelaiye-Ogala R et al
2017/01/01
Species: Mouse PubMed
61 Villanueva J et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010 Dec;18(6):683-95
Villanueva J et al
2010/01/01
Species: Human PubMed
62 Lupberger J et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011 May;17(5):589-95
Lupberger J et al
2011/01/01
Species: Human PubMed
63 Noh K et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 2017 Dec;21(10):2785-2795
Noh K et al
2017/01/01
Species: Human PubMed
64 Chauvin C et al. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Rep 2017 Nov;21(7):1737-1745
Chauvin C et al
2017/01/01
Species: Human PubMed
65 Bax DA et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 2009 Sep;15(18):5753-61
Bax DA et al
2009/01/01
Species: Human PubMed
66 Shimamura T et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul;68(14):5827-38
Shimamura T et al
2008/01/01
Species: Human PubMed
67 Eckstein N et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009 Apr;69(7):2996-3003
Eckstein N et al
2009/01/01
Species: Human PubMed
68 Dewaele B et al. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res. 2010 Sep;70(18):7304-14
Dewaele B et al
2010/01/01
Species: Human PubMed
69 Marston E et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood 2009 Jan;113(1):117-26
Marston E et al
2009/01/01
Species: Human PubMed
70 Davies KD et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE 2013;8(12):e82236
Davies KD et al
2013/01/01
Species: Human PubMed
71 Oliveras-Ferraros C et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int. J. Oncol. 2010 Sep;37(3):669-78
Oliveras-Ferraros C et al
2010/01/01
Species: Human PubMed
72 Koivunen JP et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008 Jul;14(13):4275-83
Koivunen JP et al
2008/01/01
Species: Human PubMed
73 Buck E et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008 Oct;68(20):8322-32
Buck E et al
2008/01/01
Species: Human PubMed
74 Wang L et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007 Dec;110(12):4111-9
Wang L et al
2007/01/01
Species: Human PubMed
75 Oliveras-Ferraros C et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br. J. Cancer 2012 Apr;106(8):1406-14
Oliveras-Ferraros C et al
2012/01/01
Species: Human PubMed
76 Godshalk SE et al. A Variant in a MicroRNA complementary site in the 3" UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 2011 Mar;30(13):1542-50
Godshalk SE et al
2011/01/01
Species: Human PubMed
77 Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 May;316(5827):1039-43
Engelman JA et al
2007/01/01
Species: Human PubMed
78 Mansouri R et al. Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells. Cell Death Dis 2017 06;8(6):e2902
Mansouri R et al
2017/01/01
Species: Human PubMed
79 Daneshmanesh AH et al. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE 2018;13(6):e0198038
Daneshmanesh AH et al
2018/01/01
Species: Human PubMed
80 Oura K et al. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncol. Rep. 2017 Nov;38(5):2825-2835
Oura K et al
2017/01/01
Species: Human PubMed
81 Tang WH et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J. Clin. Invest. 2011 Nov;121(11):4462-76
Tang WH et al
2011/01/01
Species: Human PubMed
82 Tani T et al. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol. Cancer Ther. 2016 Jan;15(1):162-71
Tani T et al
2016/01/01
Species: Human PubMed
83 Flanigan SA et al. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin. Cancer Res. 2010 Nov;16(22):5436-46
Flanigan SA et al
2010/01/01
Species: Human PubMed
84 Malchers F et al. Mechanisms of Primary Drug Resistance in <i>FGFR1</i>-Amplified Lung Cancer. Clin. Cancer Res. 2017 Sep;23(18):5527-5536
Malchers F et al
2017/01/01
Species: Human PubMed
85 Carrasco-Garc鱈a E et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp. Cell Res. 2011 Jun;317(10):1476-89
Carrasco-Garc鱈a E et al
2011/01/01
Species: Human PubMed
86 Agarwal S et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer 2009 Mar;100(6):941-9
Agarwal S et al
2009/01/01
Species: Human PubMed
87 Eckstein N et al. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J. Biol. Chem. 2008 Jan;283(2):739-50
Eckstein N et al
2008/01/01
Species: Human PubMed
88 Kawaguchi K et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009 Jul;30(7):1097-105
Kawaguchi K et al
2009/01/01
Species: Human PubMed
89 Donson AM et al. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol. Cancer Ther. 2018 Sep;17(9):1984-1994
Donson AM et al
2018/01/01
Species: Human PubMed
90 Haas B et al. Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 2018;18:69
Haas B et al
2018/01/01
Species: Human PubMed
91 Chen W et al. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 09;77(18):5107-5117
Chen W et al
2017/01/01
Species: Human PubMed
92 Stacchiotti S et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol. Cancer Ther. 2010 May;9(5):1286-97
Stacchiotti S et al
2010/01/01
Species: Human PubMed
93 Stommel JM et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007 Oct;318(5848):287-90
Stommel JM et al
2007/01/01
Species: Human PubMed
94 Ninomiya K et al. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Sci Rep 2018 Jan;8(1):1955
Ninomiya K et al
2018/01/01
Species: Human PubMed
95 Kang HG et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-105
Kang HG et al
2007/01/01
Species: Human PubMed
96 Negri T et al. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin. Cancer Res. 2010 Jul;16(14):3581-93
Negri T et al
2010/01/01
Species: Human PubMed
97 Suda K et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 2010 Nov;16(22):5489-98
Suda K et al
2010/01/01
PubMed
98 Fujikawa T et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J. Biol. Chem. 2007 Mar;282(12):8741-8
Fujikawa T et al
2007/01/01
Species: Human PubMed
99 Str旦bel P et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br. J. Cancer 2010 Jul;103(2):196-200
Str旦bel P et al
2010/01/01
Species: Human PubMed
100 Nazarian R et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 Dec;468(7326):973-7
Nazarian R et al
2010/01/01
Species: Human PubMed
101 Ding W et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010 Oct;116(16):2984-93
Ding W et al
2010/01/01
Species: Human PubMed
102 Henriksson ML et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am. J. Pathol. 2011 Mar;178(3):1387-94
Henriksson ML et al
2011/01/01
Species: Human PubMed
103 Kotani H et al. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene 2018 Mar;37(13):1775-1787
Kotani H et al
2018/01/01
Species: Human PubMed
104 Kobayashi T et al. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells. Kidney Int. 2009 Jun;75(11):1173-83
Kobayashi T et al
2009/01/01
Species: Human PubMed
105 Kang HG et al. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol. Cancer Ther. 2010 May;9(5):1396-407
Kang HG et al
2010/01/01
Species: Human PubMed
106 McKinley ET et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res. 2011 May;17(10):3332-40
McKinley ET et al
2011/01/01
Species: Human PubMed
107 Eiselleova L et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells 2009 Aug;27(8):1847-57
Eiselleova L et al
2009/01/01
Species: Human PubMed
108 Cohen EE et al. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun;66(12):6296-303
Cohen EE et al
2006/01/01
PubMed
109 Yoon YK et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009 Sep;8(9):2526-36
Yoon YK et al
2009/01/01
Species: Human PubMed
110 Stacchiotti S et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin. Cancer Res. 2009 Feb;15(3):1096-104
Stacchiotti S et al
2009/01/01
Species: Human PubMed
111 Vultur A et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 2014 Apr;33(14):1850-61
Vultur A et al
2014/01/01
Species: Human PubMed
112 Lyons A et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J. Biol. Chem. 2017 10;292(41):16983-16998
Lyons A et al
2017/01/01
Species: Human PubMed
113 Yamaguchi T et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun 2016;7:10060
Yamaguchi T et al
2016/01/01
Species: Human PubMed
114 Lampada A et al. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death Differ. 2017 06;24(6):1045-1062
Lampada A et al
2017/01/01
Species: Human PubMed
115 Roorda BD et al. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. Eur. J. Cancer 2010 Mar;46(5):974-82
Roorda BD et al
2010/01/01
Species: Human PubMed
116 Yu L et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol. Med. ;14(5-6):264-75
Yu L et al
Species: Human PubMed
117 Lomas AC et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem. J. 2007 Aug;405(3):417-28
Lomas AC et al
2007/01/01
Species: Human PubMed
118 Fan PD et al. <i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc. Natl. Acad. Sci. U.S.A. 2018 06;115(26):E6030-E6038
Fan PD et al
2018/01/01
PubMed
119 Fukuda K et al. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status. Cancer Res. 2019 Apr;79(7):1658-1670
Fukuda K et al
2019/01/01
PubMed
120 Linkous A et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep 2019 Mar;26(12):3203-3211.e5
Linkous A et al
2019/01/01
PubMed
121 Owusu BY et al. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget 2017 Sep;8(38):63014-63025
Owusu BY et al
2017/01/01
PubMed
122 Y叩ng端ez E et al. Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target. Nat Commun 2018 09;9(1):3679
Y叩ng端ez E et al
2018/01/01
PubMed
123 Sun S et al. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation. Cell Death Dis 2018 Sep;9(9):929
Sun S et al
2018/01/01
PubMed
124 Fang Z et al. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-&#x3B2;/STAT3 Pathway. Cell. Physiol. Biochem. 2018;47(5):1751-1768
Fang Z et al
2018/01/01
PubMed
125 Sramek M et al. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a <i>PDGFRB</i> Mutation Associated with Infantile Myofibromatosis. Int J Mol Sci 2018 Sep;19(9)
Sramek M et al
2018/01/01
PubMed
126 Painuly U et al. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget 2018 Oct;9(77):34582-34594
Painuly U et al
2018/01/01
PubMed
127 Graves-Deal R et al. Broad-spectrum receptor tyrosine kinase inhibitors overcome <i>de novo</i> and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget 2019 Feb;10(13):1320-1333
Graves-Deal R et al
2019/01/01
PubMed
128 Choi SH et al. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6<sup>+</sup> cancer cell and macrophage polarization. Nat Commun 2018 11;9(1):5108
Choi SH et al
2018/01/01
PubMed
129 Xiao Z et al. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Oncotarget 2019 Apr;10(26):2546-2560
Xiao Z et al
2019/01/01
PubMed
130 He L et al. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. J. Exp. Clin. Cancer Res. 2019 Feb;38(1):84
He L et al
2019/01/01
PubMed
131 Heliste J et al. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target. BMC Cardiovasc Disord 2018 10;18(1):196
Heliste J et al
2018/01/01
PubMed
132 Wang X et al. The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors. Mol. Cancer Ther. 2019 Mar;18(3):667-679
Wang X et al
2019/01/01
PubMed
133 Boichuk S et al. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Molecules 2018 Oct;23(10)
Boichuk S et al
2018/01/01
PubMed
134 Ahmed TA et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep 2019 Jan;26(1):65-78.e5
Ahmed TA et al
2019/01/01
PubMed
135 Menendez JA et al. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 2006 Aug;24(23):3735-46
Menendez JA et al
2006/01/01
PubMed
136 Kurimchak AM et al. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. Mol. Cancer Res. 2019 Aug;17(8):1721-1734
Kurimchak AM et al
2019/01/01
PubMed
137 Aarnio-Peterson M et al. Altered Met receptor phosphorylation and LRP1-mediated uptake in cells lacking carbohydrate-dependent lysosomal targeting. J. Biol. Chem. 2017 09;292(36):15094-15104
Aarnio-Peterson M et al
2017/01/01
PubMed
138 Chakrabarty A et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2012 Feb;109(8):2718-23
Chakrabarty A et al
2012/01/01
PubMed
139 Herr R et al. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene 2018 Mar;37(12):1576-1593
Herr R et al
2018/01/01
PubMed
140 Agaram NP et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 2008 May;14(10):3204-15
Agaram NP et al
2008/01/01
PubMed
141 Kunii K et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008 Apr;68(7):2340-8
Kunii K et al
2008/01/01
PubMed
142 Kashiwagi K et al. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci. 2009 May;84(19-20):650-6
Kashiwagi K et al
2009/01/01
PubMed
143 Krzyzaniak MA et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9(4):e1003309
Krzyzaniak MA et al
2013/01/01
PubMed
144 Patwardhan PP et al. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Mol. Cancer Ther. 2018 11;17(11):2329-2340
Patwardhan PP et al
2018/01/01
PubMed
145 Ball SG et al. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells 2012 Mar;30(3):548-60
Ball SG et al
2012/01/01
PubMed
146 Bai Y et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012 May;72(10):2501-11
Bai Y et al
2012/01/01
PubMed
147 Chen ST et al. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene 2018 Jul;
Chen ST et al
2018/01/01
PubMed
148 Tanizaki J et al. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer 2011 Sep;105(6):807-13
Tanizaki J et al
2011/01/01
PubMed
149 Greenall SA et al. Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3. Transl Oncol 2018 Aug;11(4):971-978
Greenall SA et al
2018/01/01
PubMed
150 Klameth L et al. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. J Cancer 2017;8(10):1733-1743
Klameth L et al
2017/01/01
PubMed
151 van der Waals LM et al. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep 2019 Jan;9(1):819
van der Waals LM et al
2019/01/01
PubMed
152 Mueller KL et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008 May;68(9):3314-22
Mueller KL et al
2008/01/01
PubMed
153 Leonard B et al. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res. 2018 Aug;78(15):4331-4343
Leonard B et al
2018/01/01
PubMed
154 Okon IS et al. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells. J. Biol. Chem. 2014 Jan;289(3):1639-48
Okon IS et al
2014/01/01
PubMed
155 Mao F et al. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. Oncogenesis 2018 Feb;7(2):13
Mao F et al
2018/01/01
PubMed
156 Pearson HE et al. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol. Cancer Ther. 2018 01;17(1):204-214
Pearson HE et al
2018/01/01
PubMed
157 Ciaglia E et al. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor. Int. J. Cancer 2017 02;140(4):959-972
Ciaglia E et al
2017/01/01
PubMed
158 Karki R et al. The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation. PLoS Pathog. 2011 Apr;7(4):e1001331
Karki R et al
2011/01/01
PubMed
159 Jin HO et al. Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochem. Biophys. Res. Commun. 2017 May;486(4):1083-1089
Jin HO et al
2017/01/01
PubMed
160 Jung SN et al. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. Sci Rep 2018 Feb;8(1):2718
Jung SN et al
2018/01/01
PubMed
161 Goldoni S et al. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009 May;185(4):743-54
Goldoni S et al
2009/01/01
PubMed
162 Ou WB et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011 Jan;13(1):12-22
Ou WB et al
2011/01/01
PubMed
163 Sin STK et al. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol. Oncol. 2019 01;152(1):185-193
Sin STK et al
2019/01/01
PubMed
164 Hsu HP et al. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. Sci Rep 2017 Jul;7(1):5823
Hsu HP et al
2017/01/01
PubMed
165 Tanabe H et al. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. Int. J. Oncol. 2011 Jul;39(1):33-40
Tanabe H et al
2011/01/01
PubMed
166 Rao S et al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J. Biol. Chem. 2019 May;294(21):8664-8673
Rao S et al
2019/01/01
PubMed
167 Ganesh K et al. Prostaglandin E&#x2082; induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J. Immunol. 2012 Sep;189(5):2563-73
Ganesh K et al
2012/01/01
PubMed
168 Wang D et al. Protein C receptor stimulates multiple signaling pathways in breast cancer cells. J. Biol. Chem. 2018 01;293(4):1413-1424
Wang D et al
2018/01/01
PubMed
169 Ball SG et al. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J. Cell Biol. 2007 May;177(3):489-500
Ball SG et al
2007/01/01
PubMed
170 Csepeggi C et al. Somatic cell plasticity and Niemann-pick type C2 protein: adipocyte differentiation and function. J. Biol. Chem. 2010 Sep;285(39):30347-54
Csepeggi C et al
2010/01/01
PubMed
171 Miyata K et al. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep 2017 Jun;7(1):4059
Miyata K et al
2017/01/01
PubMed
172 Jang WJ et al. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J. Cell. Mol. Med. 2019 Feb;23(2):1106-1115
Jang WJ et al
2019/01/01
PubMed
173 Poulikakos PI et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 Dec;480(7377):387-90
Poulikakos PI et al
2011/01/01
PubMed
174 Virz狸 AR et al. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proc. Natl. Acad. Sci. U.S.A. 2018 10;115(40):10058-10063
Virz狸 AR et al
2018/01/01
PubMed
175 Cook SA et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 2010 Jan;31(1):100-11
Cook SA et al
2010/01/01
PubMed
176 Franovic A et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc. Natl. Acad. Sci. U.S.A. 2009 Dec;106(50):21306-11
Franovic A et al
2009/01/01
PubMed
177 Csepeggi C et al. Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation. J. Biol. Chem. 2011 Jan;286(3):2078-87
Csepeggi C et al
2011/01/01
PubMed
178 Ding VM et al. Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells. PLoS ONE 2011;6(3):e17538
Ding VM et al
2011/01/01
PubMed
179 Jiao Y et al. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol. Cancer 2011;10:125
Jiao Y et al
2011/01/01
PubMed
180 Sulahian R et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep 2019 10;29(1):118-134.e8
Sulahian R et al
2019/01/01
PubMed
181 Nakai S et al. Establishment of a novel human CIC-DUX<sub>4</sub> sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs. Sci Rep 2019 11;9(1):15812
Nakai S et al
2019/01/01
PubMed
182 Manabe T et al. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Mol Cancer Res 2020 04;18(4):549-559
Manabe T et al
2020/01/01
PubMed
183 Matsui T et al. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int J Mol Sci 2019 Jun;20(13)
Matsui T et al
2019/01/01
PubMed
184 Skoda J et al. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. Cancers (Basel) 2020 Jan;12(1)
Skoda J et al
2020/01/01
PubMed
185 Sato T et al. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. Cancer Res 2019 12;79(24):6084-6100
Sato T et al
2019/01/01
PubMed
186 Njah K et al. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. Cell Rep 2019 07;28(4):949-965.e7
Njah K et al
2019/01/01
PubMed
187 Meng F et al. EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nat Commun 2019 11;10(1):5033
Meng F et al
2019/01/01
PubMed
188 Kuo MT et al. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Transl Oncol 2020 Feb;13(2):355-364
Kuo MT et al
2020/01/01
PubMed
189 Lee N et al. 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met. Metabolites 2019 Sep;9(9)
Lee N et al
2019/01/01
PubMed
190 MacFarland SP et al. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Mol Cancer Ther 2020 03;19(3):920-926
MacFarland SP et al
2020/01/01
PubMed
191 Zhang Q et al. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas. BMC Cancer 2019 Nov;19(1):1044
Zhang Q et al
2019/01/01
PubMed
192 de Laat MA et al. An investigation of the equine epidermal growth factor system during hyperinsulinemic laminitis. PLoS One 2019;14(12):e0225843
de Laat MA et al
2019/01/01
PubMed
193 Kim J et al. STAT3 Relays a Differential Response to Melanoma-Associated <i>NRAS</i> Mutations. Cancers (Basel) 2020 Jan;12(1)
Kim J et al
2020/01/01
PubMed
194 Lee J et al. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers (Basel) 2020 Jan;12(2)
Lee J et al
2020/01/01
PubMed
195 Singh N et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med 2021 05;27(5):842-850
Singh N et al
2021/01/01
Species: Human PubMed
196 Yanagitani N et al. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci 2020 Mar;111(3):932-939
Yanagitani N et al
2020/01/01
Species: Human PubMed
197 Pietrobono S et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nat Commun 2020 11;11(1):5865
Pietrobono S et al
2020/01/01
Species: Human PubMed
198 Mahdal M et al. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFR&#x3B2; Signaling. Cancers (Basel) 2021 Jul;13(14)
Mahdal M et al
2021/01/01
Species: Human PubMed
199 Fuentes-Baile M et al. Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. Cancers (Basel) 2020 Dec;12(12)
Fuentes-Baile M et al
2020/01/01
Species: Human PubMed
200 Zhang P et al. Effect of cyclic mechanical loading on immunoinflammatory microenvironment in biofabricating hydroxyapatite scaffold for bone regeneration. Bioact Mater 2021 Oct;6(10):3097-3108
Zhang P et al
2021/01/01
Species: Human PubMed
201 Morishita A et al. Galectin&#x2011;9 suppresses the tumor growth of colon cancer <i>in&#xA0;vitro</i> and <i>in&#xA0;vivo</i>. Oncol Rep 2021 Jun;45(6)
Morishita A et al
2021/01/01
Species: Human PubMed
202 Areeb Z et al. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep 2020 10;10(1):17768
Areeb Z et al
2020/01/01
Species: Human PubMed
203 Lee PC et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Oncogene 2020 03;39(13):2724-2740
Lee PC et al
2020/01/01
Species: Human PubMed
204 Roy S et al. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers (Basel) 2020 Aug;12(8)
Roy S et al
2020/01/01
Species: Human PubMed
205 Holl坦si P et al. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules 2020 09;10(10)
Holl坦si P et al
2020/01/01
Species: Human PubMed
206 Zhou B et al. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling. Nat Microbiol 2020 12;5(12):1576-1587
Zhou B et al
2020/01/01
Species: Human PubMed
207 Lee SJ et al. Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling. Cancers (Basel) 2021 Jun;13(11)
Lee SJ et al
2021/01/01
Species: Human PubMed
208 Lee J et al. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells. Onco Targets Ther 2021;14:3813-3820
Lee J et al
2021/01/01
Species: Human PubMed
209 Cheng CL et al. CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway. Cells 2020 07;9(7)
Cheng CL et al
2020/01/01
Species: Human PubMed
210 Liao WC et al. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. Oncogenesis 2020 Feb;9(2):9
Liao WC et al
2020/01/01
Species: Human PubMed
211 Lee ES et al. Sarmentosamide, an Anti-Aging Compound from a Marine-Derived <i>Streptomyces</i> sp. APmarine042. Mar Drugs 2020 Sep;18(9)
Lee ES et al
2020/01/01
Species: Human PubMed
  • No.: 1
  • 文献情報:
    Lorenzon E et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 2012 Jun;31(26):3136-47
    Lorenzon E et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Gowrishankar K et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol. 2012 Jul;132(7):1850-9
    Gowrishankar K et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Ho AL et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012 Sep;72(17):4515-25
    Ho AL et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Kotani N et al. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J. Biol. Chem. 2012 Oct;287(44):37109-18
    Kotani N et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Joshi AD et al. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE 2012;7(10):e44372
    Joshi AD et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Lin SP et al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS ONE 2012;7(11):e49605
    Lin SP et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Duncan JS et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012 Apr;149(2):307-21
    Duncan JS et al
    2012/01/01
  • 備考:
    Sample Type: Tissue Homogenates
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Purushothaman A et al. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J. Biol. Chem. 2012 Nov;287(49):41288-96
    Purushothaman A et al
    2012/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Montero JC et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2014 Jan;33(2):148-56
    Montero JC et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Britschgi A et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl. Acad. Sci. U.S.A. 2013 Mar;110(11):E1026-34
    Britschgi A et al
    2013/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Kwon HS et al. Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling. J. Biol. Chem. 2013 Sep;288(37):26357-71
    Kwon HS et al
    2013/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Ugurel S et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin. Cancer Res. 2014 Jan;20(2):499-510
    Ugurel S et al
    2014/01/01
  • 備考:
    Sample Type: Tissue Lysate
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Lei H et al. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor &#x3B1;. Mol. Cell. Biol. 2014 Jan;34(1):110-22
    Lei H et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Son MY et al. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency. Hum. Mol. Genet. 2014 Apr;23(7):1802-16
    Son MY et al
    2014/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Drake JM et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl. Acad. Sci. U.S.A. 2013 Dec;110(49):E4762-9
    Drake JM et al
    2013/01/01
  • 備考:
    Sample Type: Homogenized Tissue
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Skoda J et al. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol. Rep. 2014 Jan;31(1):480-7
    Skoda J et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    de-Freitas-Junior JC et al. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. PLoS ONE 2013;8(11):e81579
    de-Freitas-Junior JC et al
    2013/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Lekawanvijit S et al. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS ONE 2013;8(12):e83687
    Lekawanvijit S et al
    2013/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Carlino MS et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014 May;8(3):544-54
    Carlino MS et al
    2014/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Sakanyan V et al. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. Sci Rep 2014;4:3977
    Sakanyan V et al
    2014/01/01
  • 備考:
    Application: Phosphorylation array, Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Camorani S et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFR&#x3B2; aptamer. Mol. Ther. 2014 Apr;22(4):828-41
    Camorani S et al
    2014/01/01
  • 備考:
    Sample Type: Cell Extract
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Banerjee J et al. Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLoS ONE 2014;9(3):e89239
    Banerjee J et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Miyagawa-Yamaguchi A et al. Expressed glycosylphosphatidylinositol-anchored horseradish peroxidase identifies co-clustering molecules in individual lipid raft domains. PLoS ONE 2014;9(3):e93054
    Miyagawa-Yamaguchi A et al
    2014/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Cuenca-L坦pez MD et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014;14:302
    Cuenca-L坦pez MD et al
    2014/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Wang LK et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS ONE 2014;9(5):e96765
    Wang LK et al
    2014/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Wang J et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 2014 Jun;
    Wang J et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Outani H et al. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer 2014;14:455
    Outani H et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Shiono M et al. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. Sci Rep 2014;4:5927
    Shiono M et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Imura Y et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol. Cancer 2014;13:185
    Imura Y et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Puzanov I et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res. 2015 Feb;21(4):701-11
    Puzanov I et al
    2015/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Zemskova MY et al. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell. Signal. 2015 Jan;27(1):135-46
    Zemskova MY et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Tworkoski K et al. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J. Virol. 2015 Mar;89(5):2590-602
    Tworkoski K et al
    2015/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Wu JR et al. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS ONE 2015;10(1):e0114495
    Wu JR et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Laukkanen MO et al. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI. PLoS ONE 2015;10(3):e0121441
    Laukkanen MO et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Ito K et al. Artificial human Met agonists based on macrocycle scaffolds. Nat Commun 2015;6:6373
    Ito K et al
    2015/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Broecker-Preuss M et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer 2015;15:184
    Broecker-Preuss M et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Lee H et al. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol. Cell. Biol. 2013 Apr;33(7):1430-41
    Lee H et al
    2013/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Li L et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene 2014 Aug;33(33):4253-64
    Li L et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Song W et al. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 2014 May;74(9):2444-54
    Song W et al
    2014/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Calero R et al. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS ONE 2014;9(4):e95628
    Calero R et al
    2014/01/01
  • 備考:
    Sample Type: Protien Lysates
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Ji Z et al. MITF Modulates Therapeutic Resistance through EGFR Signaling. J. Invest. Dermatol. 2015 Jul;135(7):1863-72
    Ji Z et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Chung S et al. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS ONE 2015;10(8):e0134948
    Chung S et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    Song A et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Clin. Cancer Res. 2015 May;21(10):2379-87
    Song A et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    Cohen NA et al. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res. 2015 May;75(10):2061-70
    Cohen NA et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Heim EN et al. Biologically active LIL proteins built with minimal chemical diversity. Proc. Natl. Acad. Sci. U.S.A. 2015 Aug;112(34):E4717-25
    Heim EN et al
    2015/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 46
  • 文献情報:
    Yoshida T et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE 2016;11(1):e0147344
    Yoshida T et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 47
  • 文献情報:
    Szymanska E et al. Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway. Cell. Signal. 2016 Jan;28(1):160-71
    Szymanska E et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 48
  • 文献情報:
    Huang M et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J. Clin. Invest. 2016 May;126(5):1801-14
    Huang M et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 49
  • 文献情報:
    Brandt A et al. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE 2016;11(5):e0155561
    Brandt A et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 50
  • 文献情報:
    Aghajanian H et al. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. Nat Commun 2016 Jun;7:12038
    Aghajanian H et al
    2016/01/01
  • 備考:
    Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 51
  • 文献情報:
    Cassinelli G et al. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget 2016 Jul;7(30):47848-47863
    Cassinelli G et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 52
  • 文献情報:
    Xu Y et al. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget 2016 Oct;7(43):70080-70091
    Xu Y et al
    2016/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 53
  • 文献情報:
    Nanjo S et al. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol. Cancer Ther. 2017 Mar;16(3):506-515
    Nanjo S et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 54
  • 文献情報:
    Saintas E et al. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. PLoS ONE 2017;12(2):e01
    Saintas E et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysate
  • 参照:
    PubMed
  • No.: 55
  • 文献情報:
    Nukaga S et al. Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2017 Apr;77(8):2078-2089
    Nukaga S et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 56
  • 文献情報:
    Buchanan PC et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J. Biol. Chem. 2017 Apr;292(15):6339-6351
    Buchanan PC et al
    2017/01/01
  • 備考:
    Sample Type: cell supernates
  • 参照:
    PubMed
  • No.: 57
  • 文献情報:
    Li C et al. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2017 Apr;114(14):E2852-E2861
    Li C et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 58
  • 文献情報:
    Yadav SS et al. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol 2017 Jun;10(3):357-366
    Yadav SS et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 59
  • 文献情報:
    Xu L et al. BCL6 promotes glioma and serves as a therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 2017 04;114(15):3981-3986
    Xu L et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 60
  • 文献情報:
    Adelaiye-Ogala R et al. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res. 2017 12;77(23):6651-6666
    Adelaiye-Ogala R et al
    2017/01/01
  • 備考:
    Species: Mouse
  • 参照:
    PubMed
  • No.: 61
  • 文献情報:
    Villanueva J et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010 Dec;18(6):683-95
    Villanueva J et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 62
  • 文献情報:
    Lupberger J et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011 May;17(5):589-95
    Lupberger J et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 63
  • 文献情報:
    Noh K et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 2017 Dec;21(10):2785-2795
    Noh K et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 64
  • 文献情報:
    Chauvin C et al. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Rep 2017 Nov;21(7):1737-1745
    Chauvin C et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 65
  • 文献情報:
    Bax DA et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 2009 Sep;15(18):5753-61
    Bax DA et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 66
  • 文献情報:
    Shimamura T et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul;68(14):5827-38
    Shimamura T et al
    2008/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 67
  • 文献情報:
    Eckstein N et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009 Apr;69(7):2996-3003
    Eckstein N et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 68
  • 文献情報:
    Dewaele B et al. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res. 2010 Sep;70(18):7304-14
    Dewaele B et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 69
  • 文献情報:
    Marston E et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood 2009 Jan;113(1):117-26
    Marston E et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 70
  • 文献情報:
    Davies KD et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE 2013;8(12):e82236
    Davies KD et al
    2013/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 71
  • 文献情報:
    Oliveras-Ferraros C et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int. J. Oncol. 2010 Sep;37(3):669-78
    Oliveras-Ferraros C et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 72
  • 文献情報:
    Koivunen JP et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008 Jul;14(13):4275-83
    Koivunen JP et al
    2008/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 73
  • 文献情報:
    Buck E et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008 Oct;68(20):8322-32
    Buck E et al
    2008/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 74
  • 文献情報:
    Wang L et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007 Dec;110(12):4111-9
    Wang L et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 75
  • 文献情報:
    Oliveras-Ferraros C et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br. J. Cancer 2012 Apr;106(8):1406-14
    Oliveras-Ferraros C et al
    2012/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 76
  • 文献情報:
    Godshalk SE et al. A Variant in a MicroRNA complementary site in the 3&quot; UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 2011 Mar;30(13):1542-50
    Godshalk SE et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 77
  • 文献情報:
    Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 May;316(5827):1039-43
    Engelman JA et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 78
  • 文献情報:
    Mansouri R et al. Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells. Cell Death Dis 2017 06;8(6):e2902
    Mansouri R et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 79
  • 文献情報:
    Daneshmanesh AH et al. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE 2018;13(6):e0198038
    Daneshmanesh AH et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 80
  • 文献情報:
    Oura K et al. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncol. Rep. 2017 Nov;38(5):2825-2835
    Oura K et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 81
  • 文献情報:
    Tang WH et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J. Clin. Invest. 2011 Nov;121(11):4462-76
    Tang WH et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 82
  • 文献情報:
    Tani T et al. Activation of EGFR Bypass Signaling by TGF&#x3B1; Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol. Cancer Ther. 2016 Jan;15(1):162-71
    Tani T et al
    2016/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 83
  • 文献情報:
    Flanigan SA et al. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin. Cancer Res. 2010 Nov;16(22):5436-46
    Flanigan SA et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 84
  • 文献情報:
    Malchers F et al. Mechanisms of Primary Drug Resistance in <i>FGFR1</i>-Amplified Lung Cancer. Clin. Cancer Res. 2017 Sep;23(18):5527-5536
    Malchers F et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 85
  • 文献情報:
    Carrasco-Garc鱈a E et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp. Cell Res. 2011 Jun;317(10):1476-89
    Carrasco-Garc鱈a E et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 86
  • 文献情報:
    Agarwal S et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer 2009 Mar;100(6):941-9
    Agarwal S et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 87
  • 文献情報:
    Eckstein N et al. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J. Biol. Chem. 2008 Jan;283(2):739-50
    Eckstein N et al
    2008/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 88
  • 文献情報:
    Kawaguchi K et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009 Jul;30(7):1097-105
    Kawaguchi K et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 89
  • 文献情報:
    Donson AM et al. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol. Cancer Ther. 2018 Sep;17(9):1984-1994
    Donson AM et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 90
  • 文献情報:
    Haas B et al. Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 2018;18:69
    Haas B et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 91
  • 文献情報:
    Chen W et al. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 09;77(18):5107-5117
    Chen W et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 92
  • 文献情報:
    Stacchiotti S et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol. Cancer Ther. 2010 May;9(5):1286-97
    Stacchiotti S et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 93
  • 文献情報:
    Stommel JM et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007 Oct;318(5848):287-90
    Stommel JM et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 94
  • 文献情報:
    Ninomiya K et al. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Sci Rep 2018 Jan;8(1):1955
    Ninomiya K et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 95
  • 文献情報:
    Kang HG et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-105
    Kang HG et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 96
  • 文献情報:
    Negri T et al. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin. Cancer Res. 2010 Jul;16(14):3581-93
    Negri T et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 97
  • 文献情報:
    Suda K et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 2010 Nov;16(22):5489-98
    Suda K et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 98
  • 文献情報:
    Fujikawa T et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J. Biol. Chem. 2007 Mar;282(12):8741-8
    Fujikawa T et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 99
  • 文献情報:
    Str旦bel P et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br. J. Cancer 2010 Jul;103(2):196-200
    Str旦bel P et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 100
  • 文献情報:
    Nazarian R et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 Dec;468(7326):973-7
    Nazarian R et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 101
  • 文献情報:
    Ding W et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010 Oct;116(16):2984-93
    Ding W et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 102
  • 文献情報:
    Henriksson ML et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am. J. Pathol. 2011 Mar;178(3):1387-94
    Henriksson ML et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 103
  • 文献情報:
    Kotani H et al. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene 2018 Mar;37(13):1775-1787
    Kotani H et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 104
  • 文献情報:
    Kobayashi T et al. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells. Kidney Int. 2009 Jun;75(11):1173-83
    Kobayashi T et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 105
  • 文献情報:
    Kang HG et al. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol. Cancer Ther. 2010 May;9(5):1396-407
    Kang HG et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 106
  • 文献情報:
    McKinley ET et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res. 2011 May;17(10):3332-40
    McKinley ET et al
    2011/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 107
  • 文献情報:
    Eiselleova L et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells 2009 Aug;27(8):1847-57
    Eiselleova L et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 108
  • 文献情報:
    Cohen EE et al. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun;66(12):6296-303
    Cohen EE et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 109
  • 文献情報:
    Yoon YK et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009 Sep;8(9):2526-36
    Yoon YK et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 110
  • 文献情報:
    Stacchiotti S et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin. Cancer Res. 2009 Feb;15(3):1096-104
    Stacchiotti S et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 111
  • 文献情報:
    Vultur A et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 2014 Apr;33(14):1850-61
    Vultur A et al
    2014/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 112
  • 文献情報:
    Lyons A et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J. Biol. Chem. 2017 10;292(41):16983-16998
    Lyons A et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 113
  • 文献情報:
    Yamaguchi T et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun 2016;7:10060
    Yamaguchi T et al
    2016/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 114
  • 文献情報:
    Lampada A et al. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death Differ. 2017 06;24(6):1045-1062
    Lampada A et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 115
  • 文献情報:
    Roorda BD et al. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. Eur. J. Cancer 2010 Mar;46(5):974-82
    Roorda BD et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 116
  • 文献情報:
    Yu L et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol. Med. ;14(5-6):264-75
    Yu L et al
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 117
  • 文献情報:
    Lomas AC et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem. J. 2007 Aug;405(3):417-28
    Lomas AC et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 118
  • 文献情報:
    Fan PD et al. <i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc. Natl. Acad. Sci. U.S.A. 2018 06;115(26):E6030-E6038
    Fan PD et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 119
  • 文献情報:
    Fukuda K et al. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status. Cancer Res. 2019 Apr;79(7):1658-1670
    Fukuda K et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 120
  • 文献情報:
    Linkous A et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep 2019 Mar;26(12):3203-3211.e5
    Linkous A et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 121
  • 文献情報:
    Owusu BY et al. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget 2017 Sep;8(38):63014-63025
    Owusu BY et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 122
  • 文献情報:
    Y叩ng端ez E et al. Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target. Nat Commun 2018 09;9(1):3679
    Y叩ng端ez E et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 123
  • 文献情報:
    Sun S et al. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation. Cell Death Dis 2018 Sep;9(9):929
    Sun S et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 124
  • 文献情報:
    Fang Z et al. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-&#x3B2;/STAT3 Pathway. Cell. Physiol. Biochem. 2018;47(5):1751-1768
    Fang Z et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 125
  • 文献情報:
    Sramek M et al. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a <i>PDGFRB</i> Mutation Associated with Infantile Myofibromatosis. Int J Mol Sci 2018 Sep;19(9)
    Sramek M et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 126
  • 文献情報:
    Painuly U et al. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget 2018 Oct;9(77):34582-34594
    Painuly U et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 127
  • 文献情報:
    Graves-Deal R et al. Broad-spectrum receptor tyrosine kinase inhibitors overcome <i>de novo</i> and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget 2019 Feb;10(13):1320-1333
    Graves-Deal R et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 128
  • 文献情報:
    Choi SH et al. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6<sup>+</sup> cancer cell and macrophage polarization. Nat Commun 2018 11;9(1):5108
    Choi SH et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 129
  • 文献情報:
    Xiao Z et al. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Oncotarget 2019 Apr;10(26):2546-2560
    Xiao Z et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 130
  • 文献情報:
    He L et al. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. J. Exp. Clin. Cancer Res. 2019 Feb;38(1):84
    He L et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 131
  • 文献情報:
    Heliste J et al. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target. BMC Cardiovasc Disord 2018 10;18(1):196
    Heliste J et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 132
  • 文献情報:
    Wang X et al. The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors. Mol. Cancer Ther. 2019 Mar;18(3):667-679
    Wang X et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 133
  • 文献情報:
    Boichuk S et al. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Molecules 2018 Oct;23(10)
    Boichuk S et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 134
  • 文献情報:
    Ahmed TA et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep 2019 Jan;26(1):65-78.e5
    Ahmed TA et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 135
  • 文献情報:
    Menendez JA et al. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 2006 Aug;24(23):3735-46
    Menendez JA et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 136
  • 文献情報:
    Kurimchak AM et al. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. Mol. Cancer Res. 2019 Aug;17(8):1721-1734
    Kurimchak AM et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 137
  • 文献情報:
    Aarnio-Peterson M et al. Altered Met receptor phosphorylation and LRP1-mediated uptake in cells lacking carbohydrate-dependent lysosomal targeting. J. Biol. Chem. 2017 09;292(36):15094-15104
    Aarnio-Peterson M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 138
  • 文献情報:
    Chakrabarty A et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2012 Feb;109(8):2718-23
    Chakrabarty A et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 139
  • 文献情報:
    Herr R et al. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene 2018 Mar;37(12):1576-1593
    Herr R et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 140
  • 文献情報:
    Agaram NP et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 2008 May;14(10):3204-15
    Agaram NP et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 141
  • 文献情報:
    Kunii K et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008 Apr;68(7):2340-8
    Kunii K et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 142
  • 文献情報:
    Kashiwagi K et al. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci. 2009 May;84(19-20):650-6
    Kashiwagi K et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 143
  • 文献情報:
    Krzyzaniak MA et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9(4):e1003309
    Krzyzaniak MA et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 144
  • 文献情報:
    Patwardhan PP et al. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Mol. Cancer Ther. 2018 11;17(11):2329-2340
    Patwardhan PP et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 145
  • 文献情報:
    Ball SG et al. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells 2012 Mar;30(3):548-60
    Ball SG et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 146
  • 文献情報:
    Bai Y et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012 May;72(10):2501-11
    Bai Y et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 147
  • 文献情報:
    Chen ST et al. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene 2018 Jul;
    Chen ST et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 148
  • 文献情報:
    Tanizaki J et al. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br. J. Cancer 2011 Sep;105(6):807-13
    Tanizaki J et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 149
  • 文献情報:
    Greenall SA et al. Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3. Transl Oncol 2018 Aug;11(4):971-978
    Greenall SA et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 150
  • 文献情報:
    Klameth L et al. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. J Cancer 2017;8(10):1733-1743
    Klameth L et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 151
  • 文献情報:
    van der Waals LM et al. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep 2019 Jan;9(1):819
    van der Waals LM et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 152
  • 文献情報:
    Mueller KL et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008 May;68(9):3314-22
    Mueller KL et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 153
  • 文献情報:
    Leonard B et al. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res. 2018 Aug;78(15):4331-4343
    Leonard B et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 154
  • 文献情報:
    Okon IS et al. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells. J. Biol. Chem. 2014 Jan;289(3):1639-48
    Okon IS et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 155
  • 文献情報:
    Mao F et al. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. Oncogenesis 2018 Feb;7(2):13
    Mao F et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 156
  • 文献情報:
    Pearson HE et al. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol. Cancer Ther. 2018 01;17(1):204-214
    Pearson HE et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 157
  • 文献情報:
    Ciaglia E et al. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor. Int. J. Cancer 2017 02;140(4):959-972
    Ciaglia E et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 158
  • 文献情報:
    Karki R et al. The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation. PLoS Pathog. 2011 Apr;7(4):e1001331
    Karki R et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 159
  • 文献情報:
    Jin HO et al. Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochem. Biophys. Res. Commun. 2017 May;486(4):1083-1089
    Jin HO et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 160
  • 文献情報:
    Jung SN et al. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. Sci Rep 2018 Feb;8(1):2718
    Jung SN et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 161
  • 文献情報:
    Goldoni S et al. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009 May;185(4):743-54
    Goldoni S et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 162
  • 文献情報:
    Ou WB et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011 Jan;13(1):12-22
    Ou WB et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 163
  • 文献情報:
    Sin STK et al. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol. Oncol. 2019 01;152(1):185-193
    Sin STK et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 164
  • 文献情報:
    Hsu HP et al. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. Sci Rep 2017 Jul;7(1):5823
    Hsu HP et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 165
  • 文献情報:
    Tanabe H et al. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. Int. J. Oncol. 2011 Jul;39(1):33-40
    Tanabe H et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 166
  • 文献情報:
    Rao S et al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J. Biol. Chem. 2019 May;294(21):8664-8673
    Rao S et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 167
  • 文献情報:
    Ganesh K et al. Prostaglandin E&#x2082; induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J. Immunol. 2012 Sep;189(5):2563-73
    Ganesh K et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 168
  • 文献情報:
    Wang D et al. Protein C receptor stimulates multiple signaling pathways in breast cancer cells. J. Biol. Chem. 2018 01;293(4):1413-1424
    Wang D et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 169
  • 文献情報:
    Ball SG et al. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J. Cell Biol. 2007 May;177(3):489-500
    Ball SG et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 170
  • 文献情報:
    Csepeggi C et al. Somatic cell plasticity and Niemann-pick type C2 protein: adipocyte differentiation and function. J. Biol. Chem. 2010 Sep;285(39):30347-54
    Csepeggi C et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 171
  • 文献情報:
    Miyata K et al. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep 2017 Jun;7(1):4059
    Miyata K et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 172
  • 文献情報:
    Jang WJ et al. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J. Cell. Mol. Med. 2019 Feb;23(2):1106-1115
    Jang WJ et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 173
  • 文献情報:
    Poulikakos PI et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 Dec;480(7377):387-90
    Poulikakos PI et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 174
  • 文献情報:
    Virz狸 AR et al. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proc. Natl. Acad. Sci. U.S.A. 2018 10;115(40):10058-10063
    Virz狸 AR et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 175
  • 文献情報:
    Cook SA et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 2010 Jan;31(1):100-11
    Cook SA et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 176
  • 文献情報:
    Franovic A et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc. Natl. Acad. Sci. U.S.A. 2009 Dec;106(50):21306-11
    Franovic A et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 177
  • 文献情報:
    Csepeggi C et al. Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation. J. Biol. Chem. 2011 Jan;286(3):2078-87
    Csepeggi C et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 178
  • 文献情報:
    Ding VM et al. Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells. PLoS ONE 2011;6(3):e17538
    Ding VM et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 179
  • 文献情報:
    Jiao Y et al. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol. Cancer 2011;10:125
    Jiao Y et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 180
  • 文献情報:
    Sulahian R et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep 2019 10;29(1):118-134.e8
    Sulahian R et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 181
  • 文献情報:
    Nakai S et al. Establishment of a novel human CIC-DUX<sub>4</sub> sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs. Sci Rep 2019 11;9(1):15812
    Nakai S et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 182
  • 文献情報:
    Manabe T et al. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Mol Cancer Res 2020 04;18(4):549-559
    Manabe T et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 183
  • 文献情報:
    Matsui T et al. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int J Mol Sci 2019 Jun;20(13)
    Matsui T et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 184
  • 文献情報:
    Skoda J et al. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. Cancers (Basel) 2020 Jan;12(1)
    Skoda J et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 185
  • 文献情報:
    Sato T et al. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. Cancer Res 2019 12;79(24):6084-6100
    Sato T et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 186
  • 文献情報:
    Njah K et al. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. Cell Rep 2019 07;28(4):949-965.e7
    Njah K et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 187
  • 文献情報:
    Meng F et al. EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nat Commun 2019 11;10(1):5033
    Meng F et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 188
  • 文献情報:
    Kuo MT et al. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Transl Oncol 2020 Feb;13(2):355-364
    Kuo MT et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 189
  • 文献情報:
    Lee N et al. 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met. Metabolites 2019 Sep;9(9)
    Lee N et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 190
  • 文献情報:
    MacFarland SP et al. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Mol Cancer Ther 2020 03;19(3):920-926
    MacFarland SP et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 191
  • 文献情報:
    Zhang Q et al. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas. BMC Cancer 2019 Nov;19(1):1044
    Zhang Q et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 192
  • 文献情報:
    de Laat MA et al. An investigation of the equine epidermal growth factor system during hyperinsulinemic laminitis. PLoS One 2019;14(12):e0225843
    de Laat MA et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 193
  • 文献情報:
    Kim J et al. STAT3 Relays a Differential Response to Melanoma-Associated <i>NRAS</i> Mutations. Cancers (Basel) 2020 Jan;12(1)
    Kim J et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 194
  • 文献情報:
    Lee J et al. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers (Basel) 2020 Jan;12(2)
    Lee J et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 195
  • 文献情報:
    Singh N et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med 2021 05;27(5):842-850
    Singh N et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 196
  • 文献情報:
    Yanagitani N et al. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci 2020 Mar;111(3):932-939
    Yanagitani N et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 197
  • 文献情報:
    Pietrobono S et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nat Commun 2020 11;11(1):5865
    Pietrobono S et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 198
  • 文献情報:
    Mahdal M et al. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFR&#x3B2; Signaling. Cancers (Basel) 2021 Jul;13(14)
    Mahdal M et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 199
  • 文献情報:
    Fuentes-Baile M et al. Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. Cancers (Basel) 2020 Dec;12(12)
    Fuentes-Baile M et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 200
  • 文献情報:
    Zhang P et al. Effect of cyclic mechanical loading on immunoinflammatory microenvironment in biofabricating hydroxyapatite scaffold for bone regeneration. Bioact Mater 2021 Oct;6(10):3097-3108
    Zhang P et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 201
  • 文献情報:
    Morishita A et al. Galectin&#x2011;9 suppresses the tumor growth of colon cancer <i>in&#xA0;vitro</i> and <i>in&#xA0;vivo</i>. Oncol Rep 2021 Jun;45(6)
    Morishita A et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 202
  • 文献情報:
    Areeb Z et al. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep 2020 10;10(1):17768
    Areeb Z et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 203
  • 文献情報:
    Lee PC et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Oncogene 2020 03;39(13):2724-2740
    Lee PC et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 204
  • 文献情報:
    Roy S et al. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers (Basel) 2020 Aug;12(8)
    Roy S et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 205
  • 文献情報:
    Holl坦si P et al. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules 2020 09;10(10)
    Holl坦si P et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 206
  • 文献情報:
    Zhou B et al. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling. Nat Microbiol 2020 12;5(12):1576-1587
    Zhou B et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 207
  • 文献情報:
    Lee SJ et al. Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling. Cancers (Basel) 2021 Jun;13(11)
    Lee SJ et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 208
  • 文献情報:
    Lee J et al. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells. Onco Targets Ther 2021;14:3813-3820
    Lee J et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 209
  • 文献情報:
    Cheng CL et al. CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway. Cells 2020 07;9(7)
    Cheng CL et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 210
  • 文献情報:
    Liao WC et al. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. Oncogenesis 2020 Feb;9(2):9
    Liao WC et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 211
  • 文献情報:
    Lee ES et al. Sarmentosamide, an Anti-Aging Compound from a Marine-Derived <i>Streptomyces</i> sp. APmarine042. Mar Drugs 2020 Sep;18(9)
    Lee ES et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed